Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma
Conditions
Interventions
CHF6001
Placebo
Locations
3
United Kingdom
Hammersmith Medicines Research
London, United Kingdom
Respiratory Clinical Trials
London, United Kingdom
Medicines Evaluation Unit
Manchester, United Kingdom
Start Date
October 1, 2012
Primary Completion Date
April 1, 2013
Completion Date
April 1, 2013
Last Updated
March 30, 2017
NCT07219173
NCT07486401
NCT02327897
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions